These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

518 related articles for article (PubMed ID: 32302411)

  • 41. Antiviral effects of azithromycin: A narrative review.
    Khoshnood S; Shirani M; Dalir A; Moradi M; Haddadi MH; Sadeghifard N; Birjandi FS; Yashmi I; Heidary M
    Biomed Pharmacother; 2022 Mar; 147():112682. PubMed ID: 35131658
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Azithromycin added to hydroxychloroquine for patients admitted to intensive care due to coronavirus disease 2019 (COVID-19)-protocol of randomised controlled trial AZIQUINE-ICU.
    Duška F; Waldauf P; Halačová M; Zvoníček V; Bala J; Balík M; Beneš J; Klementová O; Kozáková I; Kubricht V; Le Roy A; Vymazal T; Řehořová V; Černý V;
    Trials; 2020 Jul; 21(1):631. PubMed ID: 32641163
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hydroxychloroquine and azithromycin as potential treatments for COVID-19; clinical status impacts the outcome.
    Okour M; Al-Kofahi M; Austin D
    J Pharmacokinet Pharmacodyn; 2020 Jun; 47(3):187-188. PubMed ID: 32405664
    [No Abstract]   [Full Text] [Related]  

  • 44. COVID-19 and toxicity from potential treatments: Panacea or poison.
    Wong A
    Emerg Med Australas; 2020 Aug; 32(4):697-699. PubMed ID: 32378805
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.
    Cuadrado-Lavín A; Olmos JM; Cifrian JM; Gimenez T; Gandarillas MA; García-Saiz M; Rebollo MH; Martínez-Taboada V; López-Hoyos M; Fariñas MC; Crespo J
    Trials; 2020 Jun; 21(1):472. PubMed ID: 32493494
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hydroxychloroquine and Azithromycin to Treat Patients With COVID-19: Both Friends and Foes?
    Mégarbane B; Scherrmann JM
    J Clin Pharmacol; 2020 Jul; 60(7):808-814. PubMed ID: 32434282
    [No Abstract]   [Full Text] [Related]  

  • 47. Chloroquine and hydroxychloroquine in covid-19.
    Ferner RE; Aronson JK
    BMJ; 2020 Apr; 369():m1432. PubMed ID: 32269046
    [No Abstract]   [Full Text] [Related]  

  • 48. Hydroxychloroquine efficacy and safety in preventing SARS-CoV-2 infection and COVID-19 disease severity during pregnancy (COVID-Preg): a structured summary of a study protocol for a randomised placebo controlled trial.
    González R; García-Otero L; Pons-Duran C; Marbán-Castro E; Goncé A; Llurba E; Gil MDM; Rodríguez-Zambrano MÁ; Chen H; Ramírez M; Bardají A; Menendez C
    Trials; 2020 Jul; 21(1):607. PubMed ID: 32616063
    [TBL] [Abstract][Full Text] [Related]  

  • 49. ChemoPROphyLaxIs with hydroxychloroquine For covId-19 infeCtious disease (PROLIFIC) to prevent covid-19 infection in frontline healthcare workers: A structured summary of a study protocol for a randomised controlled trial.
    McEniery CM; Fisk M; Miles K; Kaloyirou F; Hubsch A; Smith J; Wilkinson IB; Cheriyan J
    Trials; 2020 Jul; 21(1):604. PubMed ID: 32616067
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Existing highly accumulating lysosomotropic drugs with potential for repurposing to target COVID-19.
    Norinder U; Tuck A; Norgren K; Munic Kos V
    Biomed Pharmacother; 2020 Oct; 130():110582. PubMed ID: 32763818
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Psychopharmacology of COVID-19.
    Bilbul M; Paparone P; Kim AM; Mutalik S; Ernst CL
    Psychosomatics; 2020; 61(5):411-427. PubMed ID: 32425246
    [TBL] [Abstract][Full Text] [Related]  

  • 52. COVID-19 Drugs Chloroquine and Hydroxychloroquine, but Not Azithromycin and Remdesivir, Block hERG Potassium Channels.
    Szendrey M; Guo J; Li W; Yang T; Zhang S
    J Pharmacol Exp Ther; 2021 May; 377(2):265-272. PubMed ID: 33674391
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Use of hydroxychloroquine and azithromycin combination to treat the COVID-19 infection.
    Bajpai J; Pradhan A; Verma AK; Kant S
    World J Exp Med; 2022 May; 12(3):44-52. PubMed ID: 35765514
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Direct inhibitory effect on viral entry of influenza A and SARS-CoV-2 viruses by azithromycin.
    Du X; Zuo X; Meng F; Han C; Ouyang W; Han Y; Gu Y; Zhao X; Xu F; Qin FX
    Cell Prolif; 2021 Jan; 54(1):e12953. PubMed ID: 33211371
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety considerations for chloroquine and hydroxychloroquine in the treatment of COVID-19.
    Gevers S; Kwa MSG; Wijnans E; van Nieuwkoop C
    Clin Microbiol Infect; 2020 Sep; 26(9):1276-1277. PubMed ID: 32422406
    [No Abstract]   [Full Text] [Related]  

  • 56. A short focus, azithromycin in the treatment of respiratory viral infection COVID-19: efficacy or inefficacy?
    Vitiello A; Ferrara F
    Immunol Res; 2022 Feb; 70(1):129-133. PubMed ID: 34739696
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Azithromycin Use in COVID-19 Patients: Implications on the Antimicrobial Resistance.
    Seabra G; Ventura Mendes RF; Dos Santos Amorim LFV; Peregrino IV; Branquinha MH; Dos Santos ALS; Nunes APF
    Curr Top Med Chem; 2021; 21(8):677-683. PubMed ID: 34028347
    [No Abstract]   [Full Text] [Related]  

  • 58. Azithromycin: Immunomodulatory and antiviral properties for SARS-CoV-2 infection.
    Khezri MR; Zolbanin NM; Ghasemnejad-Berenji M; Jafari R
    Eur J Pharmacol; 2021 Aug; 905():174191. PubMed ID: 34015317
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Weight of Evidence From Electrophysiology, Observational, and Cardiovascular End Point Studies Demonstrates the Safety of Azithromycin.
    Cook J; Pressler ML; Damle B; Alemayehu D; Knirsch CA
    Clin Transl Sci; 2021 Jan; 14(1):106-112. PubMed ID: 32956575
    [TBL] [Abstract][Full Text] [Related]  

  • 60. COVID-19 and antimalarials. Have we been doing it wrong all along?
    Cismaru CA; Cismaru GL; Seyed Nabavi F; Seyed Nabavi M; Berindan-Neagoe I
    Eur J Pharmacol; 2021 Jan; 891():173694. PubMed ID: 33130275
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.